Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.9
Journals
JCM
Special Issues
Clinic Advances in Non-Small-Cell Lung Cancer
share announcement

Clinic Advances in Non-Small-Cell Lung Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 7260

Special Issue Editors

Dr. Abed Agbarya

E-Mail
Guest Editor
Bnai Zion Medical Centre, Oncology Division and Cancer Institute, Haifa 31048, Israel
Interests: lung cancer; immunotherapy; molecular profiling; targeted treatments; COVID-19 and cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Elizabeth Dudnik

E-Mail Website
Guest Editor
Head of the Lung Cancer Service, Assuta Medical Centers, Tel-Aviv, Israel
Interests: immune checkpoint inhibitors; non-small-cell lung cancer; circulating tumor DNA; EGFR mutations; radiotherapy
Dr. Maximilian J. Hochmair

E-Mail
Guest Editor
Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Krankenhaus Nord, 3500 Vienna, Austria
Interests: metastatic non-small-cell lung cancer; clinical trial; chemotherapy monoclonal antibody drugs; EGFR mutation positive
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Non-small-cell lung cancer (NSCLC), which accounts for 85% of lung cancer cases, is clinically presented as a plethora of genetically mutated tumors. The novel research associated with detecting specific DNA alterations has led to the discovery of drugs which are able to target gene variants. Treating patients with lung cancer is a challenge due to late-stage diagnosis and thus high mortality. An active approach with early screening will increase patient survival rates by offering the molecular profiling of tumor biopsy, hence targeting individual proteins such as inhibiting Tyrosine Kinase. Immunotherapy using immune checkpoint inhibitors (ICI) aims to block PD and PD-L1 proteins associated with balancing the immune system activity, hence allowing a stronger anticancer immune response. Examples of ICIs approved by the FDA as adjuvant and neoadjuvant agents provide first and second lines of treatments, including consolidation, are Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, and Pembrolizumab. In addition, NSCLC-accepted therapies use inhibitors to attack certain cancer cells with ALK alterations, which tend to have disease progression in the brain. Among the recent pharmaceutical agents are Alectinib, Brigatinib, and Lorlatinib. ROS1 mutated gene in NSCLC makes changes in cell signalling affecting cell growth. To counteract the ROS1 protein, crizotinib and entrectinib are used for treating these patients. Moreover, to decrease the spread and growth of NSCLC cells, a combination of the drugs trametinib, acting on kinase proteins called MEK and dabrafenib, and inhibiting B-Raf involvement in cellular signal transduction is used to treat certain patients. Blocking EGFR function is important to stop the abnormally high division activity linked to this receptor through administering Osimertinib, Gefitinib, Erlotinib, Dacomitinib, and Afatinib. Ongoing clinical trials address several issues expressed by NSCLC patients, among them CNS metastases and resistance to TKI. Recent studies show emerging encouraging results of drug combinations emphasizing the clinician’s discretion to be aware of the medical publications allowing them to tailor the best care and drug of choice available to each patient.

The present Special Issue aims to explore “Clinic Advances in Non-Small-Cell Lung Cancer” by compiling the most significant recent breakthroughs in the topics concerning novel drug development and updated therapeutic applications. The highlights sections are:

  1. Early detection involving low-dose CT scans for heavy smokers aided by computer algorithms to identify cancer and predict outcomes;
  2. Biological markers circulating in the blood or sputum such as abnormal tumor cells the or molecular presence of suspicious cancer-related proteins;
  3. Immunotherapy (IO) including various combinations with chemotherapy in first and second and consolidation;
  4. Adjuvant-targeted and IO-improving DFS;
  5. BBB penetration ability of Alectinib and Tagrisso (Osimertinib) to treat NSCLC brain metastases;
  6. Uncovering resistance mechanisms to TKI and investigations researching adjustments to treatment protocols,
  7. Using sensitive technology to analyse circulating tumorous DNA.

Dr. Abed Agbarya
Dr. Elizabeth Dudnik
Dr. Maximilian J. Hochmair
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-small-cell lung cancer
  • immunotherapy
  • molecular genetics and proteomics profiling
  • mutation-targeted anticancer drug
  • tumor drug resistance
  • new therapeutic molecules
  • individualized tailored medicine
  • biological markers in blood or sputum
  • chemotherapy
  • early detection

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

16 pages, 583 KiB  
Article
Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study
by Oliver Illini, Hannah Fabikan, Maximilian Johannes Hochmair, Christoph Weinlinger, Dagmar Krenbek, Luka Brcic, Ulrike Setinek, Angelika Terbuch, Gudrun Absenger, Selma Konjić and Arschang Valipour
J. Clin. Med. 2022, 11(14), 4098; https://doi.org/10.3390/jcm11144098 - 15 Jul 2022
Cited by 3 | Viewed by 2605
Abstract
About 15% of patients with non-small cell lung cancer (NSCLC) harbor the Kirsten rat sarcoma homolog G12C mutation (KRASG12C). Selective KRASG12C inhibitors offer new treatment opportunities, but little is known about the prevalence, characteristics, and outcomes of standard-of-care treatment [...] Read more.
About 15% of patients with non-small cell lung cancer (NSCLC) harbor the Kirsten rat sarcoma homolog G12C mutation (KRASG12C). Selective KRASG12C inhibitors offer new treatment opportunities, but little is known about the prevalence, characteristics, and outcomes of standard-of-care treatment (SOC) in this population. We retrospectively assessed the clinicopathological features of patients with KRASG12C-mutated advanced NSCLC and responses to SOC at two high-volume centers in Austria. Out of 2495 NSCLC patients tested, we identified 174 patients with advanced-stage disease carrying a KRASG12C mutation. Most patients were ≥65 years old (55%), heavy smokers (55%), and presented with comorbidities. The most frequent co-alteration was TP53 (18%). PD-L1 expression was high (TPS ≥ 50%) in 31%, very high (TPS ≥ 90%) in 11%, and negative in 31% of patients. A total of 138 patients (79%) received oncologic systemic treatment. The most common first-line therapy (1 L) was anti-PD-1/PD-L1 plus platinum-based chemotherapy. Median overall survival measured from 1 L treatment was 15.3 months (95% CI, 8.6–21.9), 9.4 (95% CI, 5.3–13.5) from 2 L treatment, and 8.4 (95% CI, 1.7–15.1) from 3 L treatment. The time-to-next-treatment was 8.4 (95% CI, 5.2–11.6) from 1 L and 6.1 (95% CI, 2.7–9.7) months from 2 L to 3 L. These poor outcomes underscore the need for the implementation of new treatment options and for specific molecular testing. Full article
(This article belongs to the Special Issue Clinic Advances in Non-Small-Cell Lung Cancer)
►▼ Show Figures

Figure 1

10 pages, 1590 KiB  
Article
Associations between Covariates and Pneumothorax Observations in CT-Guided Lung Biopsies
by Nour Maalouf, Daniela Lavric, Lora Vasileva, Wolfram Lamadé and Jonas Apitzsch
J. Clin. Med. 2022, 11(7), 1958; https://doi.org/10.3390/jcm11071958 - 1 Apr 2022
Cited by 1 | Viewed by 1671
Abstract
The purpose of this study is to assess the effect of nine covariates on the occurrence or absence of stable or symptomatic pneumothorax. Forty-three patients underwent CT-guided lung biopsies from January 2020 to January 2022 (24 m, 19 f, median age 70 years). [...] Read more.
The purpose of this study is to assess the effect of nine covariates on the occurrence or absence of stable or symptomatic pneumothorax. Forty-three patients underwent CT-guided lung biopsies from January 2020 to January 2022 (24 m, 19 f, median age 70 years). All the interventions were carried out with a semi-automatic 18G needle and a 17G trocar in a prone or supine position. Different covariates were measured and correlated to the rate and severity of the pneumothoraces observed. Nominal two-sided t-test p-values for the continuous variables and Fisher’s exact test results for the categorical variables were conducted. The data included the lesion size, distance to the pleura, needle-pleura angle, age, gender, position during the procedure, and the presence of chronic obstructive pulmonary disease. Patients with an observed pneumothorax had an average angle between the needle and the pleura of 74.00° compared to 94.68° in patients with no pneumothorax (p-value = 0.028). A smaller angle measurement correlated with a higher risk of pneumothorax development. The needle-pleural angle plays a vital role in the outcome of a CT-guided lung biopsy. Correctly adjusting the needle-pleural angle can diminish the pneumothorax risk associated with a CT-guided lung biopsy. The study results show that as the needle’s angle deviates from the perpendicular, the pleural surface area experiencing trauma increases, and pneumothorax is more likely to occur. Full article
(This article belongs to the Special Issue Clinic Advances in Non-Small-Cell Lung Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Research

18 pages, 6291 KiB  
Systematic Review
Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis
by Tai-Huang Lee, Hsiao-Ling Chen, Hsiu-Mei Chang, Chiou-Mei Wu, Kuan-Li Wu, Chia-Yu Kuo, Po-Ju Wei, Chin-Ling Chen, Hui-Lin Liu, Jen-Yu Hung, Chih-Jen Yang and Inn-Wen Chong
J. Clin. Med. 2022, 11(12), 3366; https://doi.org/10.3390/jcm11123366 - 12 Jun 2022
Cited by 3 | Viewed by 2143
Abstract
Patients with advanced non-small cell lung cancer (NSCLC) who harbor susceptible epidermal growth factor receptor (EGFR) mutations and are treated with EGFR tyrosine kinase inhibitors (TKIs) show longer progression-free survival (PFS) than those treated with chemotherapy. However, developed EGFR-TKI resistance limits PFS improvements. [...] Read more.
Patients with advanced non-small cell lung cancer (NSCLC) who harbor susceptible epidermal growth factor receptor (EGFR) mutations and are treated with EGFR tyrosine kinase inhibitors (TKIs) show longer progression-free survival (PFS) than those treated with chemotherapy. However, developed EGFR-TKI resistance limits PFS improvements. Currently, combination treatment with EGFR-TKIs and anti-angiogenic agents is considered a beneficial regimen for advanced-stage NSCLC harboring susceptible EGFR mutations. However, several trials reported osimertinib plus bevacizumab failed to show superior efficacy over osimertinib alone. However, subgroup analysis showed significantly longer PFS among patients with a history of smoking over those who never smoked. We performed a comprehensive systematic review and meta-analysis to evaluate the smoking status impact. At the end of the process, a total of 2068 patients from 11 randomized controlled trials (RCTs) were included in our meta-analysis. Overall, combination EGFR-TKI plus anti-angiogenic agent treatment showed significantly better PFS among patients with a smoking history (Hazard Ratio (HR) = 0.59, 95% confidence interval (CI) = 0.48–0.73). Erlotinib-based combination therapy showed positive PFS benefits regardless of smoking status (HR = 0.54, 95%CI = 0.41–0.71 for ever smoker, HR = 0.69, 95%CI = 0.54–0.87 for never smoker). Combination therapy prolonged PFS significantly regardless of ethnicity (HR: 0.64, 95% CI: 0.44–0.93 for Asian RCTs, HR: 0.55, 95% CI: 0.41–0.74 for global and non-Asian RCTs). PROSPERO registration number is CRD42022304198). Full article
(This article belongs to the Special Issue Clinic Advances in Non-Small-Cell Lung Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop